HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Metabotropic glutamate receptor 5, and its trafficking molecules Norbin and Tamalin, are increased in the CA1 hippocampal region of subjects with schizophrenia.

Abstract
Metabotropic glutamate receptor 5 (mGluR5) is involved in hippocampal-dependent learning and memory, which are processes disrupted in schizophrenia. Recent evidence from human genetic and animal studies suggests that the regulation of mGluR5, including its interaction with trafficking molecules, may be altered in the disorder. However there have been no investigations of hippocampal mGluR5 or mGluR5 trafficking molecules in the postmortem schizophrenia brain to confirm this. In the present study, we investigated whether protein expression of mGluR5, as well as Norbin and Tamalin (modulators of mGluR5 signalling and trafficking), might be altered in the schizophrenia brain, using postmortem samples from the hippocampal CA1 region of schizophrenia subjects and matched controls (n=20/group). Protein levels of mGluR5 (total: 42%, p<0.001; monomer: 25%, p=0.011; dimer: 52%, p<0.001) and mGluR5 trafficking molecules (Norbin: 47%, p<0.001; Tamalin: 34%, p=0.009) were significantly higher in schizophrenia subjects compared to controls. To determine any influence of antipsychotic drug treatment, all proteins were also correlated with lifetime chlorpromazine equivalents in patients, and separately measured in the hippocampus of rats exposed to haloperidol or olanzapine treatment. mGluR5 was negatively correlated with lifetime antipsychotic drug exposure in schizophrenia patients, suggesting antipsychotic drugs could reduce mGluR5 protein in schizophrenia subjects. In contrast, mGluR5 and mGluR5 trafficking molecules were not altered in the hippocampus of antipsychotic drug treated rats. This investigation provides strong support for the hypothesis that mGluR5 is involved in the pathology of schizophrenia, and that alterations to mGluR5 trafficking might contribute to the hippocampal-dependent cognitive dysfunctions associated with this disorder.
AuthorsNatalie Matosin, Francesca Fernandez-Enright, Jeremy S Lum, Jessica L Andrews, Martin Engel, Xu-Feng Huang, Kelly A Newell
JournalSchizophrenia research (Schizophr Res) Vol. 166 Issue 1-3 Pg. 212-8 (Aug 2015) ISSN: 1573-2509 [Electronic] Netherlands
PMID26048293 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2015 Elsevier B.V. All rights reserved.
Chemical References
  • Antipsychotic Agents
  • Carrier Proteins
  • GRASP protein, rat
  • GRM5 protein, human
  • Grm5 protein, rat
  • Membrane Proteins
  • NCDN protein, human
  • Nerve Tissue Proteins
  • Neuropeptides
  • Receptor, Metabotropic Glutamate 5
  • norbin
  • tamalin protein, human
  • Benzodiazepines
  • Haloperidol
  • Olanzapine
  • Chlorpromazine
Topics
  • Animals
  • Antipsychotic Agents (pharmacology, therapeutic use)
  • Benzodiazepines (pharmacology, therapeutic use)
  • CA1 Region, Hippocampal (drug effects, metabolism)
  • Carrier Proteins (metabolism)
  • Chlorpromazine (therapeutic use)
  • Dimerization
  • Female
  • Haloperidol (pharmacology, therapeutic use)
  • Humans
  • Immunoblotting
  • Male
  • Membrane Proteins (metabolism)
  • Middle Aged
  • Nerve Tissue Proteins (metabolism)
  • Neuropeptides (metabolism)
  • Olanzapine
  • Rats, Sprague-Dawley
  • Receptor, Metabotropic Glutamate 5 (metabolism)
  • Schizophrenia (drug therapy, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: